8-KOther EventsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Corporate Update (Mar 28, 2014)

Filed March 28, 2014For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report on March 28, 2014, primarily to disclose a significant development in a consolidated shareholder derivative litigation concerning its directors and senior management. This litigation, previously disclosed in the company's 2013 10-K, involves allegations related to the drug Depakote. The company announced that on March 18, 2014, the court overseeing the case issued an order preliminarily approving a proposed settlement. This preliminary approval marks a step towards resolving the derivative lawsuits, which had consolidated eight separate cases. Investors should note that this is a preliminary approval, and a final settlement hearing will be scheduled to determine the finality of the agreement. The filing includes a notice of the proposed settlement, providing details for shareholders regarding the terms and their rights.

Key Highlights

  • 1Abbott Laboratories disclosed preliminary approval of a settlement for consolidated shareholder derivative lawsuits.
  • 2The litigation, named "In Re Abbott-Depakote Shareholder Derivative Litigation," involves allegations against current and former directors and senior management.
  • 3An eighth shareholder derivative lawsuit was consolidated into the proceeding on March 12, 2014.
  • 4The court signed an order on March 18, 2014, preliminarily approving the proposed settlement.
  • 5A final settlement hearing will be scheduled to review and potentially approve the settlement.
  • 6The filing directs investors to Exhibit 99.1, a Notice of Proposed Settlement, for further details.
  • 7This event is categorized under Item 8.01 (Other Events) of the 8-K filing.

Frequently Asked Questions

The primary reason for this 8-K filing is to announce the preliminary approval of a proposed settlement in a consolidated shareholder derivative litigation concerning Abbott Laboratories' directors and senior management, related to the drug Depakote.

Shareholder derivative lawsuits are legal actions brought by shareholders on behalf of a corporation. Typically, these suits allege that the company's directors or officers have harmed the company through negligence or misconduct, and the shareholders are seeking to recover damages for the company.

No, the settlement is not yet final. The court has issued a preliminary approval, and a final settlement hearing will be scheduled. This means the settlement terms are subject to review and final approval by the court.

More detailed information about the proposed settlement, including the terms and information about the final settlement hearing, can be found in Exhibit 99.1, titled 'Notice of Proposed Settlement of Consolidated Derivative Actions, Final Settlement Hearing, and Right to Appear,' which is filed with this 8-K report.